. Furthermore, the incidence of symptomatic hypoglycaemia with plasma glucose ≤3.9 mmol/L (≤70 mg/dL) was also analysed according to the same subgroups.
| INTRODUCTION
Current diabetes treatment guidelines suggest that if a patient with type 2 diabetes mellitus (T2DM) does not achieve glycated haemoglobin (HbA1c) targets despite treatment with basal insulin (usually in combination with metformin and/or another oral drug), the patient's regimen should be intensified with the addition of either mealtime insulin or a glucagon-like peptide-1 receptor agonist (GLP-1 RA). 1, 2 The addition of mealtime insulin to a basal regimen, while often effective at lowering glycaemia, can involve markedly increasing the patient's daily injection burden, and may be accompanied by an increased risk of weight gain and hypoglycaemia.
Adding a GLP-1 RA to a basal insulin regimen can augment glycaemic control with minimal additional risk of hypoglycaemia and without adding to the risk of weight gain associated with insulin itself, although GLP-1 RAs are often associated with gastrointestinal adverse events. Lixisenatide (Lixi: Lyxumia, Sanofi, Paris, France;
Adlyxin, Sanofi, Bridgewater, NJ, USA) is a once-daily prandial GLP-1 RA with a robust postprandial plasma glucose (PPG)-lowering effect, which is predominantly driven by delayed gastric emptying and reductions in glucose-dependent glucagon release. [3] [4] [5] [6] The rationale for combining basal insulin with Lixi is that glycaemic control can be enhanced via a dual, complementary mechanism of action offered by the two components, each of which has its own distinct mechanism: basal insulin principally lowers the patient's fasting plasma glucose (FPG), while Lixi acts predominantly by lowering PPG.
The combination of Lixi and basal insulin glargine 100 U (iGlar) as separate injections has been shown to be more effective than basal insulin alone. 7, 8 iGlarLixi, a titratable fixed-ratio combination of iGlar and Lixi, was developed for administration as a single daily injection, and therefore has the potential to increase glycaemic control without the need for additional injections.
The LixiLan-L trial showed that iGlarLixi achieved superior glycaemic control compared with iGlar in patients with advanced T2DM whose glycaemia was not adequately controlled on basal insulin in combination with up to two oral glucose-lowering drugs. iGlarLixi mitigated the weight gain observed with iGlar, did not have additional risk of hypoglycaemia compared with iGlar alone, and had a lower rate of gastrointestinal side-effects compared with data from prior studies of Lixi. 9 Similarly, in the LixiLan-O trial, iGlarLixi was superior to iGlar and to Lixi in insulin-naïve patients with T2DM inadequately controlled with metformin AE a second oral glucose-lowering drug. 10 Trials of another single injection combination of a GLP-1 RA with basal insulin, in similar populations to that of the present study, also found additional benefit of the combination over basal insulin alone.
11,12
As patients with T2DM exhibit diverse disease characteristics, it is important to determine the efficacy and safety of new treatment options across the patient spectrum. [13] [14] [15] Therefore, exploratory subpopulation analyses of data from the LixiLan-L trial were performed to assess the impact of patients' baseline characteristics of HbA1c, disease duration and body mass index (BMI) on clinical outcomes.
| MATERIALS AND METHODS

| Trial design
The full methodology of the LixiLan-L trial (NCT02058160) has been described previously in detail. 9 Briefly, LixiLan-L was an open-label, randomized, parallel-group, multinational, multicentre, 2-arm trial with treatment duration of 30 weeks. The trial was designed and monitored in accordance with Good Clinical Practice, the International Conference on Harmonization, and the Declaration of Helsinki. Institutional review boards or ethics committees at each study site approved the protocol. Each patient gave written informed consent.
| Trial population
Patients (≥18 years) with T2DM diagnosed at least 1 year prior to screening were eligible for inclusion if they had been treated with basal insulin for at least 6 months before screening and were under a stable regimen of 15 to 40 U/d (AE20%) for at least 2 months prior to screening. The permitted oral glucose-lowering therapies (a maximum of two was allowed) were metformin (>1500 mg/d or maximumtolerated dose), a sulphonylurea, a glinide, a sodium-glucose cotransporter 2 inhibitor or a dipeptidyl peptidase 4 inhibitor. Doses of any oral glucose-lowering therapies (if taken) also had to have been stable during the 3 months before screening.
| Randomization and interventions
Eligible patients entered a 6-week run-in phase during which any oral glucose-lowering drug other than metformin was stopped, patients 
| Subpopulation analysis
The exploratory subpopulation analysis presented here was designed 
| Statistical methods
A 2-way analysis of variance with last observation carried forward was used to assess comparisons between treatment groups and subpopulations for continuous data. Comparisons between treatment groups and subpopulations for categorical data were based on Cochran-Mantel-Haenszel tests. Analysis of covariance was carried out in accordance with prior publications on this study. 9 Heterogeneity was tested using the 1 degree of freedom contrast corresponding to the test of treatment by subgroup interaction.
3 | RESULTS
| Main study analysis
A total of 736 patients were randomized in the LixiLan-L trial: 367 to iGlarLixi and 369 to iGlar. Demographics and baseline characteristics were similar across the two treatment groups, and have been published previously with the primary study results. 9 In the main study analysis, the least squares mean HbA1c change from baseline was significantly greater with iGlarLixi [−1.1% (−12 mmol/mol)] than with iGlar [−0.6% (−6.6 mmol/mol)]. In total, 55% of iGlarLixi patients reached HbA1c <7% (<53 mmol/mol) compared with 30% of iGlar patients. 9 iGlarLixi also demonstrated significant reductions in 2-h PPG following a standardized liquid breakfast meal compared with iGlar. Mean body weight decreased by 0.7 kg with iGlarLixi and increased by 0.7 kg with iGlar (P < .0001). These improvements were accompanied by no increased risk of hypoglycaemia with iGlarLixi compared with iGlar.
Similar numbers of patients from the iGlarLixi and iGlar treatment groups fell into each of the subgroups based on baseline HbA1c, diabetes duration and BMI, allowing for balanced subgroup analyses.
| Glycaemic control according to baseline
HbA1c, duration of T2DM and BMI reductions from baseline to week 30 in HbA1c were consistently greater with iGlarLixi than with iGlar (P < .0001). Within both the iGlarLixi and the iGlar treatment groups, patients with baseline HbA1c ≥8% (≥64 mmol/mol) achieved significantly greater HbA1c reductions than those with baseline HbA1c <8% (<64 mmol/mol; P < .001). In each of the subpopulations based on baseline HbA1c, T2DM duration and BMI, the proportion of patients who achieved target HbA1c <7% (<53 mmol/mol) was higher with iGlarLixi than with iGlar alone (P < .0001; Figure 1A -C).
Similar to the primary LixiLan-L analyses, there were no significant differences between the 2 treatment groups in mean change in FPG from baseline to week 30 for each subpopulation, indicating the consistent titration of the basal insulin components in the study.
However, also in line with the primary results, significant reductions from baseline to week 30 in 2-h PPG during the standardized meal test were observed with iGlarLixi vs iGlar across subpopulations (P < .0001). Within both the iGlarLixi and the iGlar treatment groups, patients with baseline HbA1c ≥8% (≥64 mmol/mol) achieved significantly greater reductions in 2-h PPG than those with baseline HbA1c <8% (<64 mmol/mol; P < .001). 
| Body weight change by subpopulation
| Hypoglycaemia by subpopulation
The incidence of hypoglycaemia [defined as plasma glucose ≤3.9 mmol/L (≤70 mg/dL)] varied slightly between the HbA1c, T2DM duration and BMI subpopulations; however, no significant differences were observed ( Figure 3A-C) . The corresponding number of events per patient-year was numerically lower in the iGlarLixi group than in the iGlar group in each of the subpopulation analyses.
| DISCUSSION
The subpopulation analyses of the LixiLan-L trial presented here found that iGlarLixi was effective in all baseline subpopulations tested, including in patients with higher HbA1c, longer duration of diabetes and higher BMI. The iGlarLixi treatment group showed consistently greater glycaemic control and higher percentages of patients reaching the HbA1c target than the iGlar group across all of the sub- LixiLan-L trial, the study patients had a mean HbA1c of 8.5%
(69 mmol/mol), despite having been treated for several years with basal insulin and oral drugs. 9 In this trial, treatment with iGlar alone Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; iGlar, insulin glargine; Lixi, lixisenatide; PPG, postprandial plasma glucose; SE, standard error; T2DM, type 2 diabetes mellitus.
All data are mean AE SD unless stated otherwise.
a Between-subpopulation comparison P < .05.
b Mean difference iGlarLixi vs iGlar. Treatment comparison P-values based on 2-factor analysis of variance.
c Heterogeneity P-value = .012. Value is based on a single degree of freedom contrast of treatment differences between subgroups. prandial mechanism of action of Lixi, which has been seen in trials to lower PPG by between 3 and 8 mmol/L (54 and 144 mg/dL). 7, 8, [17] [18] [19] [20] This prandial effect, which is an important contributor to the overall glucose-lowering effect of Lixi, is mediated by a delay in gastric emptying after a meal. 6 The delay in gastric emptying is preserved in patients with diabetes, even after the loss of much of their β-cell function, allowing such patients to maintain a meaningful response to Lixi treatment.
The primary efficacy endpoint was also analysed for other prespecified subgroups (race, ethnicity, age group, sex, metformin use at screening, and number of oral drugs used at screening). Although the data are not presented here, the results of all these analyses were consistent with the overall analysis.
The results of the current exploratory analysis should be inter- 
